February 2013: Launch of prodromal cohort to investigate risk factors of PD: hypsomia, REM behavior sleep disorder (RBD), and the presence of a LRRK2 genetic mutation.
April 2013: Enrollment of (400 newly diagnosed and 200 control subjects) completed.
July 2013: First subject enrolled in the Prodromal Cohort of PPMI
September 2013: PPMI Genetics Cohort Kick-Off meeting held in New York, NY
January 2012: 300 of the 600 subjects needed for PPMI are actively enrolled in the study
March 2012: PPMI expands to a third continent—Australia. One site is selected to participate in the study
Spring 2012: PPMI Steering Committee begins discussion of the addition of a new Pre-Motor PD cohort
Fall 2012: PPMI Steering Committee begins planning for the addition of a pre-motor cohort to the study.
March 2011: PPMI-info.org access to study data and specimens becomes available coinciding with 50 subjects having completed baseline visits
August 2011: : PPMI adds a third cohort: Subjects with SWEDD (Scans without Evidence of Dopamanergic Deficit)
January 2010: Steering Committee meeting to finalize Protocol and discuss data flow and SOPs
March 2010: Investigators Meeting brings together members of the steering committee, study cores, clinical sites and MJFF; study protocols, tests and assessment details, recruitment and retention plans and outcomes are discussed
June 2010: PPMI recruitment begins; first PPMI subject is enrolled
June 2009: Protocol Task force is appointed; begins to define study design
August 2009: Steering Committee is formed
September 2009: Study Cores are selected
October 2009: Workshop to further refine core selection, define site selection process and set a timeline for study design and launch; verification study is conducted
May 2008: Workshop to define study objectives, criteria for site selection and other study parameters
February 2007: The Michael J. Fox Foundation (MJFF) Scientific Advisory Board holds a formal discussion on the need for a concerted biomarker effort
June 2007: Workshop to explore feasibility, required scientific expertise and MJFF’s role in a large-scale biomarkers study
October 2007: Workshop to further define the scientific cores that would be needed to support a large scale biomarkers study
MJFF sponsored three biomarker RFA’s and supported applications exploring clinical, imaging and biochemical biomarkers that would be useful in clinical trials